Zynex Inc Stock Price, News & Analysis

Zynex, a medical technology company, announced a new $10 million share buyback program effective from November 1, 2022, to October 31, 2023. This move follows a prior $20 million repurchase already conducted in 2022. CEO Thomas Sandgaard stated the buyback reflects the company's strong balance sheet and aims to enhance shareholder value. The buyback will be executed under SEC regulations and is expected to be funded by existing cash without materially impacting capital levels. As of November 1, 2022, Zynex had 41.6 million shares issued.

Zynex, Inc. (Nasdaq: ZYXI) reported strong third-quarter 2022 results, achieving a 19% revenue increase year-over-year to $41.5 million. The company posted a net income of $4.9 million with a diluted EPS of $0.13 and an Adjusted EBITDA of $8.1 million. Cash from operations was $7.4 million. Zynex completed a $10 million share buyback, totaling $20 million year-to-date. Guidance for Q4 estimates revenue between $48-$51 million, anticipating a 23% increase from Q4 2021.

Zynex, Inc. (NASDAQ: ZYXI) will report its third quarter 2022 financial results on October 27, 2022, at 4:15 p.m. ET. A conference call and webcast will follow to discuss the results and provide corporate updates. Founded in 1996, Zynex specializes in non-invasive medical devices for pain management and rehabilitation. This announcement is part of their regular updates on financial performance.

Zynex, Inc. (NASDAQ: ZYXI) reported record order growth for Q3 2022, with a 34% increase compared to Q3 2021 and a 12% rise sequentially over Q2 2022. The company anticipates Q3 revenue between $40.0 million and $43.0 million, alongside an adjusted EBITDA of $7.0 million to $9.0 million. Zynex reaffirmed its full-year revenue guidance of $150 to $170 million and adjusted EBITDA of $25 to $35 million, attributing its success to strong cash collections and a productive sales force despite macroeconomic challenges.

Zynex, Inc. (NASDAQ: ZYXI) announced the initiation of a large-scale clinical trial for its CM-1600 blood loss detection system, in partnership with ClinCept, LLC., and LifeSouth Community Blood Center. This trial aims to evaluate the device's specificity and sensitivity during whole blood donation processes, with expected enrollment of 227 subjects, set to complete by early 2023. CEO Thomas Sandgaard highlighted the importance of these trials in building trust for their patented Relative Index. The results could significantly impact clinical application and market acceptance of the CM-1600.

Zynex, Inc. (Nasdaq: ZYXI), a leader in non-invasive medical devices, will participate in the H.C. Wainwright Annual Global Investment Conference on September 12, 2022, at 7am ET. The event will be held virtually, with access available through the company's investor relations website. Founded in 1996, Zynex specializes in pain management and rehabilitation devices, along with innovative patient monitoring systems. Investors can follow the company's updates through its official site.

Zynex, Inc. (Nasdaq: ZYXI), a leading medical technology firm, has announced its participation in the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 11:00 am ET. The event will be held virtually, allowing interested parties to access the live and archived webcast via Zynex's investor relations page. Founded in 1996, Zynex specializes in non-invasive medical devices for pain management and rehabilitation. For further details and registration, visit their official site.

Zynex, Inc. (Nasdaq: ZYXI) has initiated enrollment in a clinical trial for its second-generation fluid monitoring system, the CM-1600, designed for apheresis procedures. The trial builds on data collected from its predicate device, the CM-1500, which received FDA clearance in February 2020. Currently, 53 subjects are participating in the study, with completion of enrollment expected by Q4 2022. Zynex aims to demonstrate the CM-1600's enhanced sensitivity and accuracy in various clinical settings to support its market value.